Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308494779> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W4308494779 abstract "Abstract Background Previous investigations suggest that systemic inflammation markers are able to provide prognostic value in several cancers. This study seeks to characterize the ability of pretreatment platelet-to-lymphocyte ratio (PLR) to prognosticate advanced or metastatic gastric cancer patients (AGC or MGC, respectively) receiving immunotherapy. Methods AGC and MGC patients exposed to PD-1 inhibitors from January 2016–August 2021 in the Chinese PLA General Hospital were recruited. Correlations between PLR and overall survival (OS), progression-free survival (PFS), and immunotherapy-associated tumor response rates were determined. Results 237 patients were enrolled for this retrospective investigation. The 6 month and 12 month PFS based on the area under the curve value was 0.60 and 0.65 (p < 0.05). based on a calculated PLR cut-off value of 139.41, The PLR < 139.41 group has a longer OS in contrast with the PLR ≥ 139.41 group (13.46 m vs 10.71 m, HR = 0.57, 95% CI 0.42–0.78, p = 0.004). The PLR < 139.41 group had a PFS of 7.93 m in contrast to the 4.75 m seen in those with PLR ≥ 139.41 group (HR = 0.57, 95% CI 0.43–0.76, p = 0.002). The disease control rate (DCR) and objective response rate (ORR) were 86.17% and 30.85%, respectively, in the PLR < 139.41 group, but were 82.52% and 32.17%, respectively in the PLR ≥ 139.41 group. Both groups did not show any marked differences in terms of ORR and DCR (p = 0.887, p = 0.476). PLR is an independent prognostic indicator for OS and PFS upon uni- and multivariate analyses (p < 0.05). Conclusions Pre-treatment PLR correlated significantly with PFS and OS in AGC and MGC patients who received immunotherapy. An elevated PLR may provide guidance on subsequent treatment options." @default.
- W4308494779 created "2022-11-12" @default.
- W4308494779 creator A5015063074 @default.
- W4308494779 creator A5064222660 @default.
- W4308494779 date "2022-11-03" @default.
- W4308494779 modified "2023-09-25" @default.
- W4308494779 title "Pretreatment platelet-to-lymphocyte ratio (PLR) as a prognosticating indicator for gastric cancer patients receiving immunotherapy" @default.
- W4308494779 cites W1875533210 @default.
- W4308494779 cites W2005941714 @default.
- W4308494779 cites W2024861438 @default.
- W4308494779 cites W2121897702 @default.
- W4308494779 cites W2227662244 @default.
- W4308494779 cites W2277073222 @default.
- W4308494779 cites W2308639964 @default.
- W4308494779 cites W2515072408 @default.
- W4308494779 cites W2589619013 @default.
- W4308494779 cites W2620132565 @default.
- W4308494779 cites W2622499649 @default.
- W4308494779 cites W2666686240 @default.
- W4308494779 cites W2755662511 @default.
- W4308494779 cites W2773307121 @default.
- W4308494779 cites W2790007912 @default.
- W4308494779 cites W2797421660 @default.
- W4308494779 cites W2806614796 @default.
- W4308494779 cites W2897062681 @default.
- W4308494779 cites W2911879897 @default.
- W4308494779 cites W2954693483 @default.
- W4308494779 cites W2998700378 @default.
- W4308494779 cites W3005410497 @default.
- W4308494779 cites W3007383444 @default.
- W4308494779 cites W3018592043 @default.
- W4308494779 cites W3033652843 @default.
- W4308494779 cites W3083986479 @default.
- W4308494779 cites W3089110714 @default.
- W4308494779 cites W3128646645 @default.
- W4308494779 cites W4206789975 @default.
- W4308494779 doi "https://doi.org/10.1007/s12672-022-00571-5" @default.
- W4308494779 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36326905" @default.
- W4308494779 hasPublicationYear "2022" @default.
- W4308494779 type Work @default.
- W4308494779 citedByCount "0" @default.
- W4308494779 crossrefType "journal-article" @default.
- W4308494779 hasAuthorship W4308494779A5015063074 @default.
- W4308494779 hasAuthorship W4308494779A5064222660 @default.
- W4308494779 hasBestOaLocation W43084947791 @default.
- W4308494779 hasConcept C121608353 @default.
- W4308494779 hasConcept C126322002 @default.
- W4308494779 hasConcept C143998085 @default.
- W4308494779 hasConcept C167135981 @default.
- W4308494779 hasConcept C2777701055 @default.
- W4308494779 hasConcept C2777761686 @default.
- W4308494779 hasConcept C71924100 @default.
- W4308494779 hasConcept C89560881 @default.
- W4308494779 hasConcept C90924648 @default.
- W4308494779 hasConceptScore W4308494779C121608353 @default.
- W4308494779 hasConceptScore W4308494779C126322002 @default.
- W4308494779 hasConceptScore W4308494779C143998085 @default.
- W4308494779 hasConceptScore W4308494779C167135981 @default.
- W4308494779 hasConceptScore W4308494779C2777701055 @default.
- W4308494779 hasConceptScore W4308494779C2777761686 @default.
- W4308494779 hasConceptScore W4308494779C71924100 @default.
- W4308494779 hasConceptScore W4308494779C89560881 @default.
- W4308494779 hasConceptScore W4308494779C90924648 @default.
- W4308494779 hasIssue "1" @default.
- W4308494779 hasLocation W43084947791 @default.
- W4308494779 hasLocation W43084947792 @default.
- W4308494779 hasLocation W43084947793 @default.
- W4308494779 hasLocation W43084947794 @default.
- W4308494779 hasOpenAccess W4308494779 @default.
- W4308494779 hasPrimaryLocation W43084947791 @default.
- W4308494779 hasRelatedWork W2105151527 @default.
- W4308494779 hasRelatedWork W2331820588 @default.
- W4308494779 hasRelatedWork W2810456594 @default.
- W4308494779 hasRelatedWork W2951130915 @default.
- W4308494779 hasRelatedWork W3009852707 @default.
- W4308494779 hasRelatedWork W3013145321 @default.
- W4308494779 hasRelatedWork W3095141535 @default.
- W4308494779 hasRelatedWork W3208090289 @default.
- W4308494779 hasRelatedWork W3210359220 @default.
- W4308494779 hasRelatedWork W4255376461 @default.
- W4308494779 hasVolume "13" @default.
- W4308494779 isParatext "false" @default.
- W4308494779 isRetracted "false" @default.
- W4308494779 workType "article" @default.